Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive ...

In the world of consumer marketing, people-based data has become the gold standard. Demographics are just the starting point. Layered on top are deep behavioural insights into what people buy, browse, ...

The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi ...

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

GSK’s antisense-based drug for chronic hepatitis B, bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval.

Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics. The ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal.